Results 201 to 210 of about 2,703,409 (308)

Total neoadjuvant therapy for rectal cancer: where are we now, where do we go? [PDF]

Clin Transl Radiat Oncol
Fleischmann M, Kristen A, Diefenhardt M, Fokas E, Rödel C.   +4 more
europepmc   +1 more source

Estimation of Subtype‐Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology‐Inspired Natural History Models

International Journal of Cancer, EarlyView.
ABSTRACT Breast cancer progression varies across molecular subtypes, influencing detection rates and prognosis. Differences in the proportion of interval cancers (PIC)—cancers detected symptomatically between scheduled screening rounds—have been observed across subtypes, likely reflecting heterogeneity in tumour growth dynamics. We applied a continuous‐
Letizia Orsini, Yuqi Zhang, Kamila Czene, Keith Humphreys   +3 more
wiley   +1 more source

Residual Invasive Disease After Neoadjuvant Therapy in Triple-Negative Breast Cancer: Risk Stratification and Postoperative Radiotherapy-Pembrolizumab Integration. [PDF]

Cancer Manag Res
Jia X, Eerdemutu, Ren Y, Yang S, Yang C, Ding Q, Lin Y.   +6 more
europepmc   +1 more source

Pretreatment EBV‐DNA/TLG‐Based Risk Stratification Is Associated With Survival Outcomes in Nonmetastatic Nasopharyngeal Carcinoma: An Exploratory Study

International Journal of Cancer, EarlyView.
ABSTRACT Whether combining pretreatment plasma Epstein–Barr virus DNA (EBV‐DNA) with 18F‐FDG PET/CT‐derived total lesion glycolysis (TLG) improves prognostic stratification in nonmetastatic nasopharyngeal carcinoma (NPC) is unclear, particularly in nonendemic populations.
Mehmet Çağrı Duymaz, Ece Özkaya Duymaz, Nazlı Ünsal, Recep Bekiş, Büşra Tozduman, Özgür Appak, Ayşe Demiral, Oğuz Çetinayak   +7 more
wiley   +1 more source

Advanced thymic epithelial tumours after neoadjuvant therapy: a narrative review of surgical challenges and strategies. [PDF]

Mediastinum
Berjaoui N, Pather M, Karapanagiotou E, Lucchese G, Patel A, Billè A.   +5 more
europepmc   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka, Johann Kornowski, Elena Laakmann, Barbara Schmalfeldt, Tim Zell, Glenn Geidel, Christoffer Gebhardt, Pia Roser, Volkmar Müller, Julian Kött   +9 more
wiley   +1 more source

Neoadjuvant Therapy

Annals of Surgery, 1999
openaire   +2 more sources

Immune exhaustion in esophageal cancer: interferon pathway dysregulation and neoadjuvant therapy response. [PDF]

Front Cell Dev Biol
Wu X, Gao S, Qi Y.
europepmc   +1 more source

Activity of Low Dose Nivolumab in Patients With Advanced Squamous Cell Carcinomas and Other Cancers

International Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors such as anti–PD‐1 antibodies are essential in cancer therapy. Emerging data suggest that lower doses may be effective and more economical, though further evidence is needed. We conducted a retrospective study at Centre Léon Bérard to assess the efficacy and safety of low‐dose nivolumab (20 mg every 3 weeks) in ...
Thibault Gauduchon, Jerome Fayette, Mona Amini‐Adle, Eve‐Marie Neidhart‐Berard, Mehdi Brahmi, Armelle Dufresne, Margaux Dupont, Clelia Coutzac, Axel de Bernardi, Philippe Toussaint, Benoite Mery, Laura Crumbach, Isabelle Ray‐Coquard, Aurélie Dutour, Marie Castets, Jean‐Yves Blay, Pierre Etienne Heudel   +16 more
wiley   +1 more source

Integrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer. [PDF]

Ther Adv Med Oncol
Zhang L, Wang J, Wan J, Wang Y, Zhang H, Wang Y, Xia F, Shen L, Zhang Z.   +8 more
europepmc   +1 more source